In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
Subscribe To Our Newsletter & Stay Updated
